Chaoju Eye Care Holdings Ltd. (HK:2219)
:2219
Want to see HK:2219 full AI Analyst Report?
2219 Stock Chart & Stats
HK$2.71
HK$0.04(1.51%)
At close: 4:00 PM EST
HK$2.71
HK$0.04(1.51%)
Day’s Range― - ―
52-Week RangeHK$2.44 - HK$3.14
Previous CloseN/A
Volume266.00K
Average Volume (3M)722.53K
Market Cap
HK$1.79B
Enterprise ValueHK$1.27B
Total Cash (Recent Filing)HK$1.49B
Total Debt (Recent Filing)HK$237.74M
Price to Earnings (P/E)8.3
Beta0.74
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.29%
Share Statistics
EPS (TTM)0.26
Shares Outstanding705,180,500
10 Day Avg. Volume521,468
30 Day Avg. Volume722,533
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)0.72
Price to Sales (P/S)1.28
P/FCF Ratio15.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)HK$1.47B
Bulls Say, Bears Say
Bulls Say
Sustained ProfitabilityHigh, multi-level margins imply the core ophthalmic services and product mix generate durable operating economics. Sustained gross and EBIT margins provide capacity to absorb cost pressures, fund medical staff and facility upkeep, and support reinvestment into higher-margin surgical services over several quarters.
Conservative Balance SheetVery low leverage gives the company financial flexibility to weather demand cycles and invest selectively. A strong equity base reduces refinancing risk, supports steady dividends or share of capital allocation to expansion, and preserves capacity for opportunistic M&A or facility investment.
Diversified Ophthalmic Business ModelA hybrid model combining clinical procedures and retail optical sales creates multiple revenue streams and cross-selling opportunities. Recurring patient visits and higher-value procedures provide structural demand and revenue resilience versus a pure retail or pure hospital model over the next few quarters.
Bears Say
Top-line WeaknessA decline in revenue signals softening demand or competitive pressure that can erode scale economics. Persistent top-line weakness limits operating leverage, makes margin recovery harder, and raises risk that investment in facilities or recruiting ophthalmologists will deliver lower incremental returns.
Sharp Free Cash Flow DropA large decline in free cash flow and weakened cash conversion reduce financial optionality. Lower FCF constrains capacity to fund capex, pay dividends, or pursue acquisitions without tapping capital markets, and increases sensitivity to working-capital swings or higher investment needs in clinics.
Falling Return On EquityDeclining ROE suggests the company’s profitability isn't keeping pace with its capital base, indicating possible capital allocation inefficiency or slower profit growth. Sustained ROE erosion can pressure shareholder returns and limit the company's ability to justify further equity-heavy investments.
Chaoju Eye Care Holdings Ltd. News
2219 FAQ
What was Chaoju Eye Care Holdings Ltd.’s price range in the past 12 months?
Chaoju Eye Care Holdings Ltd. lowest stock price was HK$2.44 and its highest was HK$3.14 in the past 12 months.
What is Chaoju Eye Care Holdings Ltd.’s market cap?
Chaoju Eye Care Holdings Ltd.’s market cap is HK$1.79B.
When is Chaoju Eye Care Holdings Ltd.’s upcoming earnings report date?
Chaoju Eye Care Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 82 days.
How were Chaoju Eye Care Holdings Ltd.’s earnings last quarter?
Chaoju Eye Care Holdings Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.11 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.11.
Is Chaoju Eye Care Holdings Ltd. overvalued?
According to Wall Street analysts Chaoju Eye Care Holdings Ltd.’s price is currently Overvalued.
Does Chaoju Eye Care Holdings Ltd. pay dividends?
Chaoju Eye Care Holdings Ltd. pays a Semiannually dividend of HK$0.242 which represents an annual dividend yield of 9.29%. See more information on Chaoju Eye Care Holdings Ltd. dividends here
What is Chaoju Eye Care Holdings Ltd.’s EPS estimate?
Chaoju Eye Care Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chaoju Eye Care Holdings Ltd. have?
Chaoju Eye Care Holdings Ltd. has 705,180,500 shares outstanding.
What happened to Chaoju Eye Care Holdings Ltd.’s price movement after its last earnings report?
Chaoju Eye Care Holdings Ltd. reported an EPS of HK$0.11 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.379%.
Which hedge fund is a major shareholder of Chaoju Eye Care Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2219
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chaoju Eye Care Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.45%
12-Months-Change
Fundamentals
Return on Equity
7.66%
Trailing 12-Months
Asset Growth
9.69%
Trailing 12-Months
Company Description
Chaoju Eye Care Holdings Ltd.
Chaoju Eye Care Holdings Limited (CECHL) manages and operates a comprehensive network of eye hospitals and optical centers throughout China. The company delivers a range of consumer-focused ophthalmic services, encompassing treatments for vision correction (such as refractive and presbyopia issues), myopia control programs, and a variety of optical products and associated services. Additionally, CECHL provides fundamental ophthalmic care for numerous conditions, including cataracts, glaucoma, diseases of the ocular fundus, ocular muscle disorders, refractive errors, pediatric ophthalmology, ocular surface and lacrimal diseases, orbital conditions, oculoplastic procedures, and ocular trauma. As of December 31, 2021, its operational footprint included 17 eye hospitals, 24 optical centers, and 2 clinics. These facilities are situated across several Chinese regions: Zhejiang, Jiangsu, Shanxi, Hebei, and Inner Mongolia. Headquartered in Beijing, China, the company was established in 1988.
Technical Analysis
EuroEyes International Eye Clinic Limited
―
C-MER Eye Care Holdings Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Options Prices
Currently, No data available
---